Among statin-treated patients, inflammation assessed by means of high-sensitivity C-
reactive protein (hsCRP) is a more powerful determinant of cardiovascular death and all …

Despite treatment with statins, patients with elevated low-density lipoprotein cholesterol
(LDL-C) and triglycerides remain at increased risk for adverse cardiovascular events …

Background Inflammation and hyperlipidaemia jointly contribute to atherothrombotic
disease. However, when people are treated with intensive statin therapy, the relative …

Metabolic syndrome (MetS) is considered a metabolic disorder that has been steadily
increasing globally and seems to parallel the increasing prevalence of obesity. It consists of …

Cardiovascular disease (CVD) is still the leading cause of death globally, and
atherosclerosis is the main pathological basis of CVDs. Low-density lipoprotein cholesterol …

Cardiovascular disease (CVD) is the number one cause of death worldwide, which propels
the development of advanced technologies for CVD diagnosis and treatment. Biomarker …

Atherosclerosis (AS) is a major contributor to cardiovascular diseases, necessitating the
development of novel therapeutic strategies to alleviate plaque burden. Macrophage …

Aims/hypothesis This study explored the hypothesis that significant abnormalities in the
metabolism of intestinally derived lipoproteins are present in individuals with type 2 diabetes …

One fifth of the world population live in East Asia comprising Japan, Korea, and China where
ischemic heart disease, a major component of atherosclerotic cardiovascular disease …

ApoC-III inhibits lipoprotein lipase and hepatic uptake of triglyceride-rich lipoproteins. It is
unknown whether targeting apoC-III affects hepatic steatosis in patients with …